Frequency-Dependent Corticostriatal Disinhibition Resulting from Chronic Dopamine Depletion: Role of Local Striatal cGMP and GABA-AR Signaling.
The onset of motor deficits in parkinsonism is thought to result from dopamine (DA) loss-induced corticostriatal disruption and the development of excessive cortico-basal ganglia synchronization. To gain insights into the mechanisms underlying such corticostriatal dysfunction, we conducted local field potential (LFP) recordings in rats and measured how striatal manipulations of DA, cyclic guanosine monophosphate (cGMP), and gamma-aminobutyric acid- A receptor (GABA-AR) signaling impact corticostriatal transmission at specific oscillatory frequencies. Results indicate that the degree of 6-hydroxydopamine-induced DA lesion and subsequent changes in striatal DA, cGMP, and GABA-AR signaling contribute to impair LFP suppression such that the DA-depleted striatum becomes more permissive to cortically driven oscillations at 10-20 Hz, and to a lesser extent, at 40 Hz. Notably, the corticostriatal dysfunction at 40 Hz emerged only when the degree of chronic DA lesion surpassed 90%, which coincides with the appearance of severe forelimb stepping deficits. Collectively, these results indicate that several mechanisms contribute to suppress LFP within the 10-20 Hz range, yet a critical level of striatal GABAergic activity is required for sustaining corticostriatal inhibition at 40 Hz. Both the degree and chronicity of DA lesion are major contributing factors to the severity of motor and striatal GABAergic deficits that could only be reversed by strengthening local GABA-AR function.
Department of Cellular and Molecular Pharmacology.
Vatsala R
VR
Jayasinghe
Department of Cellular and Molecular Pharmacology.
Eden
E
Flores-Barrera
Department of Neuroscience, The Chicago Medical School at Rosalind Franklin University, North Chicago, IL 60064, USA.
Anthony R
AR
West
Department of Cellular and Molecular Pharmacology.
Kuei Y
KY
Tseng
D000818:Animals; D058256:Brain Waves / Q000187:drug effects / Q000502:physiology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D006152:Cyclic GMP / Q000378:metabolism; D004298:Dopamine / Q000172:deficiency*; D005552:Forelimb / Q000503:physiopathology; D008297:Male; D009043:Motor Activity / Q000502:physiology; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000378:metabolism* / Q000473:pathology; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D018079:Receptors, GABA / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D018079:Receptors, GABA; D005680:gamma-Aminobutyric Acid; D016627:Oxidopamine; D006152:Cyclic GMP; D004298:Dopamine
basal ganglia; electrophysiology; local field potentials; oscillations; parkinsonism; plasticity